N/A N=4 Use of "Smart Wheelchairs" to Provide Independent Mobility to Visual and Mobility Impairments
Blindness · Spinal Cord Injury
Primary: Time to Complete Trial Wheelchair Course
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=93 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
Phase 2 N=20 Microvascular Coronary Disease In Women: Impact Of Ranolazine
Myocardial Ischemia
Primary: Cardiac Magnetic Resonance (CMRs) — 11.7; 16.0 Percentage of ischemic myocardium
Phase 4 N=70 The Response of Pathogens to the Respective or Combined Treatment of SRP and Local Minocycline in Chronic Periodontitis
Chronic Periodontitis
Primary: Pocket Depth — 4.34; 4.81; 4.5 mm
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Phase 3 N=155 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Acromegaly
Primary: Percentage of Responders at the End of the Core Treatment Period — 86.9; 66.7; 40.4; 64.9 Percentage of responders
N/A N=83 Repair of Infected or Contaminated Hernias
Hernia
Primary: Incidence of Wound Events — 53 participants
Phase 2 N=182 Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.79; -1.87; -1.84 percentage of glycosylated haemoglobin
Phase 3 N=97 Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score — -22.9; -19.4 Units on a scale — p=<0.0001
Phase 2 N=56 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Pathologic Complete Response Rates — 8 participants
Phase 1 N=25 Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Renal Cell Cancer
Primary: Metabolic Response — 5 participants
Phase 2 N=22 Investigation of AVACEN Thermal Exchange System for Fibromyalgia Pain
Fibromyalgia
Primary: Widespread Pain Index (WPI) Score After 4 Weeks Treatment — 13.0; 8.9 units on a scale
Phase 2 N=61 Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Ovarian Neoplasms
Primary: Objective Response Rate (ORR) Investigator Assessment: % of Patients in the Group Who Achieve a Complete Response(CR) or Partial Response(PR) According to RECIST…
Phase 1 N=12 TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study
Healthy Volunteers
Primary: Part 1: Time to Reach the Maximum Plasma and Whole Blood Radioactivity Concentration (Cmax) for [14C]-TAK-385 — 2.0; 2.0 hours
Phase 2 N=168 Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12) — 84.9; 69.6; 74.5; 95 Percentage of participants